Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405846 | 0.86 | F10 (0.55) | F10ALDH1A1TSHR | |
| SCHEMBL1406097 | 0.86 | F10 (0.55) | F10ALDH1A1TSHR | |
| SCHEMBL6103822 | 0.79 | F10 (0.61) | F10FPR2 | |
| SCHEMBL6103806 | 0.79 | F10 (0.61) | F10FPR2 | |
| SCHEMBL5434234 | 0.77 | F10 (0.62) | F10KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL1405985 | 0.76 | F10 (0.54) | F10 | |
| SCHEMBL1406028 | 0.76 | F10 (0.54) | F10 | |
| SCHEMBL5440576 | 0.76 | F10 (0.60) | F10FPR2 | |
| SCHEMBL5440571 | 0.76 | F10 (0.60) | F10FPR2 | |
| SCHEMBL1405810 | 0.76 | F10 (0.85) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585730-B1 | CARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | claimed |
| US-7598241-B2 | 2-[3-(4-chlorophenyl)ureido] N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-4-methanesulfonylbutyramide; prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | claimed |
| EP-1585730-B1 | CARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-7598241-B2 | 2-[3-(4-chlorophenyl)ureido] N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-4-methanesulfonylbutyramide; prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20060074072-A1 | Carboxamide derivatives and their use as factor xa inhibitors | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074072-A1 | Carboxamide derivatives and their use as factor xa inhibitors | F11, F12, F10 | F10 3/4885KMT2A 336/4885ALDH1A1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.